Literature DB >> 12511474

Preventing stroke with ramipril--authors' reply.

Salim Yusuf, Jackie Bosch, Peter Sleight.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12511474      PMCID： PMC1124944          DOI： 10.1136/bmj.326.7379.52

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Preventing stroke with ramipril. Results should have been presented in ways that help practising clinicians.

Authors:  P Badrinath
Journal:  BMJ       Date:  2002-08-24

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Use of ramipril in preventing stroke: double blind randomised trial.

Authors:  Jackie Bosch; Salim Yusuf; Janice Pogue; Peter Sleight; Eva Lonn; Badrudin Rangoonwala; Richard Davies; Jan Ostergren; Jeff Probstfield
Journal:  BMJ       Date:  2002-03-23

4.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Authors:  L Y Agodoa; L Appel; G L Bakris; G Beck; J Bourgoignie; J P Briggs; J Charleston; D Cheek; W Cleveland; J G Douglas; M Douglas; D Dowie; M Faulkner; A Gabriel; J Gassman; T Greene; Y Hall; L Hebert; L Hiremath; K Jamerson; C J Johnson; J Kopple; J Kusek; J Lash; J Lea; J B Lewis; M Lipkowitz; S Massry; J Middleton; E R Miller; K Norris; D O'Connor; A Ojo; R A Phillips; V Pogue; M Rahman; O S Randall; S Rostand; G Schulman; W Smith; D Thornley-Brown; C C Tisher; R D Toto; J T Wright; S Xu
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

5.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.

Authors:  Andre Lamy; Salim Yusuf; Janice Pogue; Amiram Gafni
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.